JP2015172060A5 - - Google Patents

Download PDF

Info

Publication number
JP2015172060A5
JP2015172060A5 JP2015097888A JP2015097888A JP2015172060A5 JP 2015172060 A5 JP2015172060 A5 JP 2015172060A5 JP 2015097888 A JP2015097888 A JP 2015097888A JP 2015097888 A JP2015097888 A JP 2015097888A JP 2015172060 A5 JP2015172060 A5 JP 2015172060A5
Authority
JP
Japan
Prior art keywords
domain
chain
methotrexate
antibody
humanized anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015097888A
Other languages
English (en)
Japanese (ja)
Other versions
JP6154847B2 (ja
JP2015172060A (ja
Filing date
Publication date
Priority claimed from GB0817809A external-priority patent/GB0817809D0/en
Priority claimed from GB0817810A external-priority patent/GB0817810D0/en
Priority claimed from GB0817811A external-priority patent/GB0817811D0/en
Priority claimed from PCT/EP2009/052810 external-priority patent/WO2009112502A1/en
Priority claimed from PCT/EP2009/052811 external-priority patent/WO2009124815A1/en
Priority claimed from PCT/EP2009/052809 external-priority patent/WO2009121690A1/en
Application filed filed Critical
Publication of JP2015172060A publication Critical patent/JP2015172060A/ja
Publication of JP2015172060A5 publication Critical patent/JP2015172060A5/ja
Publication of JP6154847B2 publication Critical patent/JP6154847B2/ja
Application granted granted Critical
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015097888A 2008-09-29 2015-05-13 疾患治療組成物 Expired - Fee Related JP6154847B2 (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GB0817809A GB0817809D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817811.3 2008-09-29
GB0817810.5 2008-09-29
GB0817811A GB0817811D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817810A GB0817810D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817809.7 2008-09-29
EPPCT/EP2009/052809 2009-03-10
PCT/EP2009/052811 WO2009124815A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
PCT/EP2009/052810 WO2009112502A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
EPPCT/EP2009/052811 2009-03-10
PCT/EP2009/052809 WO2009121690A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
EPPCT/EP2009/052810 2009-03-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011528278A Division JP2012504110A (ja) 2008-09-29 2009-08-31 疾患治療組成物

Publications (3)

Publication Number Publication Date
JP2015172060A JP2015172060A (ja) 2015-10-01
JP2015172060A5 true JP2015172060A5 (https=) 2016-04-21
JP6154847B2 JP6154847B2 (ja) 2017-06-28

Family

ID=41138980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011528278A Pending JP2012504110A (ja) 2008-09-29 2009-08-31 疾患治療組成物
JP2015097888A Expired - Fee Related JP6154847B2 (ja) 2008-09-29 2015-05-13 疾患治療組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011528278A Pending JP2012504110A (ja) 2008-09-29 2009-08-31 疾患治療組成物

Country Status (16)

Country Link
US (1) US20110229465A1 (https=)
JP (2) JP2012504110A (https=)
KR (1) KR20110061630A (https=)
CN (1) CN102215867B (https=)
AU (1) AU2009296078B2 (https=)
BR (1) BRPI0919489A2 (https=)
CA (1) CA2738598C (https=)
CR (1) CR20110226A (https=)
DK (1) DK2341937T3 (https=)
ES (1) ES2528419T3 (https=)
IL (1) IL211904A (https=)
MX (1) MX2011003335A (https=)
PT (1) PT2341937E (https=)
RU (1) RU2531548C2 (https=)
SG (1) SG194362A1 (https=)
WO (1) WO2010034590A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
EP2260057B1 (en) * 2008-03-13 2016-11-23 Biotest AG Anti-CD4 antibody dosage regimen for treating autoimmune disease
EP2265643B1 (en) * 2008-03-13 2016-10-19 Biotest AG Dosing regimen for treating psoriasis and rheumatoid arthritis
RU2540013C2 (ru) * 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US20160158352A1 (en) * 2013-07-10 2016-06-09 The United States of America, as represented by the Secretary, Department of Health & Human Servic Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans
GB202017681D0 (en) * 2020-11-09 2020-12-23 T Balance Therapeutics Gmbh Anti-CD4 antibody or fragment thereof for medical use
DE102020129648A1 (de) * 2020-11-10 2022-05-12 Leopold MTX GmbH Pharmazeutische zusammensetzung

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
AU662891B2 (en) * 1990-11-27 1995-09-21 Biogen Idec Ma Inc. Anti CD-4 antibodies blocking HIV-induced syncytia
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
DE69427928T3 (de) * 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US20020068057A1 (en) * 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
DE19722888A1 (de) * 1997-05-28 1998-12-03 Thomas Prof Dr Huenig Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
DE60042785D1 (de) * 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
CA2410786A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of Minnesota Immunotherapeutic method to prevent islet cell rejection
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
DE10050935A1 (de) * 2000-10-11 2002-05-02 Tegenero Gmbh Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
AU2002249958B2 (en) * 2001-01-16 2007-11-08 Vascular Therapies, Inc. Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
EP1372721A4 (en) * 2001-03-07 2008-04-02 Childrens Medical Center METHOD FOR SCREENING PEPTIDE DISPLAY LIBRARIES WITH A MINIMUM DISPLAY
JP4660067B2 (ja) * 2001-04-24 2011-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血管新生剤とＴＮＦαとを用いる組合せ療法
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
DK1451224T3 (da) * 2001-12-04 2012-11-19 Theramab Llc Peptid eller protein, der indeholder en C´-D-sløjfe fra CD28-receptorfamilien
DE10212108A1 (de) * 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE10230223A1 (de) * 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7501494B2 (en) * 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
EP1613350B1 (en) * 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1600164A3 (de) * 2003-09-22 2006-05-17 TeGenero AG Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10352900A1 (de) * 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
JPWO2006035876A1 (ja) * 2004-09-29 2008-05-15 興和株式会社 関節リウマチの予防及び／又は治療薬
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
JP4730733B2 (ja) * 2005-05-02 2011-07-20 国立大学法人京都大学 ４型葉酸受容体の発現を指標とした制御性ｔ細胞の検出方法、及び免疫賦活剤
WO2007009064A2 (en) * 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AU2006290433B2 (en) * 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
CA2645322A1 (en) * 2006-03-16 2007-09-27 Genentech, Inc. Methods of treating lupus using cd4 antibodies
EP2260057B1 (en) 2008-03-13 2016-11-23 Biotest AG Anti-CD4 antibody dosage regimen for treating autoimmune disease
EP2265643B1 (en) 2008-03-13 2016-10-19 Biotest AG Dosing regimen for treating psoriasis and rheumatoid arthritis
RU2540013C2 (ru) * 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
ES2351456B1 (es) * 2009-06-24 2011-11-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b

Similar Documents

Publication Publication Date Title
JP2015172060A5 (https=)
US20240417455A1 (en) Treatment for rheumatoid arthritis
CN114286828A (zh) 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
JP2018184417A5 (https=)
JP2016147856A5 (https=)
JP2022509358A5 (https=)
Tanasescu et al. Advances in the treatment of relapsing-remitting multiple sclerosis
JP2019517549A5 (https=)
JP2022009683A (ja) テノホビルアラフェナミドの結晶形態
JP2008501712A5 (https=)
JP2014533279A5 (https=)
JP2018506550A5 (https=)
JP2019514858A5 (https=)
Takeuchi et al. Phase II dose–response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate
CN114224889A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
JP2018503610A5 (https=)
JP2020517671A5 (https=)
RU2016149316A (ru) Лечение ревматоидного артрита
JP2022532356A5 (https=)
JP2024511970A5 (https=)
RU2011117293A (ru) Композиция для лечения заболевания
CN105813637A (zh) 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂
JP2022514561A5 (https=)
Kivitz et al. FRI0209 MORAb-022, an anti-granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody (MAB): results of the first study in patients with mild-to-moderate rheumatoid arthritis (RA)
US20210023099A1 (en) Combination therapy with a bet inhibitor and a proteasome inhibitor